1-9 of 9
Dena Cohen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

Harindra Amarasinghe, PhD, Tomasz K Wojdacz, PhD MSc, Matthew John Jerome Rose-Zerilli, PhD, Alice Beattie, Jade Forster, PhD, Latha Kadalayil, Stuart Blakemore, PhD, Helen Parker, PhD, Marta Larrayoz, PhD, Ruth Clifford, Zadie Davis, Monica Else, Dena Cohen, Andrew J Steele, PhD, Richard Rosenquist, MD PhD, Andrew Collins, Andrew Pettitt, FRCPath, PhD, Peter Hillmen, MBChB, PhD, Pauline Robbe, MSc, Christopher Plass, Anna Schuh, MD PhD, Daniel Catovsky, MD FRCP, David Oscier, MD PhD, Christopher C. Oakes, PhD, Jonathan C Strefford, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 56.
https://doi.org/10.1182/blood.V130.Suppl_1.56.56
Published: 2017
Journal Articles

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Talha Munir, Peter Hillmen, MBChB, PhD, Lucy McParland, Dena Cohen, Anna Hockaday, Jamie Oughton, Fabrizio Messina, David Phillips, Jeffrey R. Neilson, FRCP,FRCPath, Nicholas Pemberton, Shankara Paneesha, MD MRCP, FRCPath, Ben Kennedy, MBChB, FRCP, FRCPath, Andy Rawstron, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3013.
https://doi.org/10.1182/blood.V130.Suppl_1.3013.3013
Published: 2017
Journal Articles

The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring

Andy C Rawstron, Dena Cohen, Ruth Mary De Tute, Lucy McParland, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, Peter Hillmen
Journal: Blood
Blood (2015) 126 (23): 1717.
https://doi.org/10.1182/blood.V126.23.1717.1717
Published: 2015
Journal Articles

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Peter Hillmen, MB ChB, PhD, Donald Milligan, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, Lucy McParland, Anna Chalmers, Tahla Munir, MB ChB, Abraham M Varghese, MB ChB, Andy C Rawstron, BSc, PhD, David J Allsup, MD, PhD, Scott Marshall, MD, Alex Smith, BSc, Corinne Collett, Walter Gregory, PhD, Andrew Duncombe, MD, Dena Cohen, BSc, MSc
Journal: Blood
Blood (2013) 122 (21): 1639.
https://doi.org/10.1182/blood.V122.21.1639.1639
Published: 2013
Journal Articles

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Austin G Kulasekararaj, MBBS, MD, Shreyans A Gandhi, MBBS, MD, Lindsay D Mitchell, MBChB, Modupe Elebute, MBChB, MD, Stephen John Richards, PhD, Matthew Cullen, MSc, Louise M Arnold, RN, BSc, Joanna Large, RN, BSc, Alexandra Wood, RN, BSc, Gemma L Brooksbank, RN, BSc, Tracy Downing, Claire McKinley, BSc, Dena Cohen, BSc, MSc, Walter M Gregory, PhD, Judith C. W. Marsh, MD, PhD, Ghulam J. Mufti, MD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2012) 120 (21): 3472.
https://doi.org/10.1182/blood.V120.21.3472.3472
Published: 2012
Journal Articles

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A. Follows, Donald Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David G. Oscier, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Andy Rawstron, PhD, Christopher F.E. Pocock, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 697.
https://doi.org/10.1182/blood.V116.21.697.697
Published: 2010
Journal Articles

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, MD, PhD, Andy Rawstron, PhD, Walter M Gregory, Alex Smith, Emma Skinner, BSc, Anne Critchley, MB, BS, Donald Milligan, MD, FRCP, FRCPath, Claire E. Dearden, MD, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen, MBChB, FRCP, FRCPath, PhD
Journal: Blood
Blood (2010) 116 (21): 60.
https://doi.org/10.1182/blood.V116.21.60.60
Published: 2010
Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock
Journal: Blood
Blood (2009) 114 (22): 3428.
https://doi.org/10.1182/blood.V114.22.3428.3428
Published: 2009
Journal Articles

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Peter Hillmen, MBChB, PhD, Christopher Pocock, MB, BS, PhD, Dena Cohen, MSc, Kim Cocks, MSc, Hazem A. Sayala, MB, BCh, Andy Rawstron, PhD, Daniel B. Kennedy, MB, ChB, Christopher Fegan, MB, BS, Don W. Milligan, MB, ChB, Claire Dearden, MB, BS, Alexandra Smith, BSc, Emma Lindop, BSc, Andrew R. Pettitt, MB, BChir, PhD
Journal: Blood
Blood (2007) 110 (11): 752.
https://doi.org/10.1182/blood.V110.11.752.752
Published: 2007